Resveratrol for PCOS: One Promising Trial, and Why That Is Not Enough

Does Resveratrol Actually Work for PCOS?

A comprehensive 2022 systematic review searching four databases through December 2020 found only three randomized, placebo-controlled human trials of resveratrol in PCOS worth including, against eight animal studies (Shojaei-Zarghani & Rafraf, 2022) — a trial base this thin is the honest starting point for anything claimed about resveratrol and PCOS. One of those three human trials is the one that matters most: a well-powered, hospital-run, placebo-controlled study published in a leading endocrinology journal. The other two are smaller and tested different outcomes. This article is built around that one trial, what it found, why the mechanism behind it is plausible, and why “one good trial” is not the same as “proven.”

What Did the One Well-Powered PCOS Trial on Resveratrol Actually Find?

Thirty-four women meeting the Rotterdam PCOS criteria were randomized 1:1 to 1,500 mg of oral resveratrol or placebo daily for 3 months at an academic hospital; 30 completed the trial (Banaszewska et al., 2016). The primary outcome was change in total testosterone, and it moved: a 23.1% decrease (p = 0.01) in the resveratrol group. Several secondary measures moved with it.

Does Resveratrol Lower Testosterone in PCOS?

Yes, in this one trial, by a clinically notable amount — but “yes, once” is the complete answer, not a settled finding. A 23% drop in total testosterone and a 22% drop in DHEA-S in the same women points to an effect on both the ovarian and adrenal sources of androgen, which is a broader signal than a single-pathway supplement usually produces. No second trial has attempted to replicate this specific result at this dose in an independent population, and replication — not one strong result — is what turns a promising finding into an established one.

What Is the Mechanism Behind Resveratrol’s Androgen Effect?

The biological rationale predates the human trial. In cultured rat ovarian theca-interstitial cells — the cell type that makes most ovarian androgen — resveratrol reduced androstenedione production by up to 78% and androsterone by up to 76%, in a dose-dependent way, and cut expression of Cyp17a1, a gene that codes for a key androgen-producing enzyme, by up to 73% (Ortega et al., 2012). The same study found the effect ran through inhibition of a cell-signalling pathway (Akt/PKB) involved in ovarian steroid production, not through the sirtuin-activation mechanism resveratrol is best known for — the researchers tested sirtuin inhibitors directly and found they did not reverse resveratrol’s effect. This is laboratory cell-culture work, not a human or even a whole-animal result, but it gives the testosterone drop seen in the human trial a specific, tested biological explanation rather than a guess.

Is There Animal Evidence for Resveratrol and PCOS?

One rat study exists using a PCOS-like model, and it points in the same direction as the human trial. Female rats given letrozole to induce a PCOS-like state, then treated with resveratrol at 40, 80, or 160 mg/kg daily for 30 days, showed increased plasma estradiol and adiponectin and more normal ovarian tissue under microscopic review than untreated PCOS-model rats, alongside increased ovarian expression of aromatase and nesfatin-1. That is a consistent signal across three different levels of evidence — cell culture, animal model, and one human trial — which is a reasonable basis for continued research. It is not, on its own, a basis for a clinical recommendation: rodent hormone physiology and dosing do not translate directly to a woman taking a supplement off a shelf, and no trial has connected the rat dose range to anything tested in the human study above.

Why Is Bioavailability the Real Problem With Resveratrol?

Even if the mechanism and the one human trial both hold up, there is a practical obstacle sitting between “resveratrol works in a study” and “your supplement delivers it”: almost none of what you swallow reaches your bloodstream as resveratrol itself. In the classic human pharmacokinetic study, six volunteers given a 25 mg oral dose of labelled resveratrol absorbed at least 70% of it — but only trace amounts, under 5 nanograms per millilitre, of unchanged resveratrol were ever detected in plasma; nearly all of it was converted within the gut and liver into sulfate and glucuronic-acid conjugates before it ever circulated intact. The study’s own authors describe this as “very low” systemic bioavailability, driven by extremely rapid sulfate conjugation.

What Resveratrol Supplement Dose Was Actually Studied for PCOS?

1,500 mg daily, for 3 months, is the only human dose with a placebo-controlled PCOS result behind it. That is well above the 250–500 mg most over-the-counter resveratrol supplements are formulated at, and above the doses most commonly sold as “high-strength.” No trial has tested a lower dose against the same PCOS outcomes, so there is no evidence a smaller, more typical supplement dose produces any part of this trial’s result. Resveratrol supplements are also sold with no requirement that a manufacturer test or disclose bioavailability-enhancing formulation — trans-resveratrol content, micronization, or a piperine/liposomal delivery system are all things a label may or may not mention, and none of them were used in the trial cited above.

How Does Resveratrol Compare to Other PCOS Supplements?

Resveratrol’s evidence sits well above zero — a real, well-designed human trial with a plausible mechanism behind it — but well below inositol, which has four separate trials measuring cycle and ovulation outcomes directly and is the only supplement the international guideline addresses by name. Inositol for PCOS covers that trial base in full. It also compares differently than saw palmetto, a supplement sold on a similarly plausible-sounding hormone story that has zero human PCOS trials behind it at all — resveratrol at least clears that bar, with one. If your specific goal is regulating cycles rather than shifting androgen and insulin numbers, resveratrol has not been tested for that outcome at all; supplements to regulate periods with PCOS ranks the options that have been. For where resveratrol sits against the rest of the field — the wider supplements and medications section — see the full evidence-ranked supplements guide.

Who This Will Not Help

• Anyone expecting a cycle or fertility benefit. The one trial measured hormones and insulin, not ovulation, cycle length, or pregnancy — there is no trial evidence for any of those outcomes.
• Anyone taking a low- or standard-dose supplement. 250–500 mg products have not been tested against any PCOS outcome; the only positive result used 1,500 mg daily.
• Anyone wanting hirsutism or acne improvement. Neither was measured in the trial that found the testosterone effect.
• Anyone who has already tried it for a few weeks and stopped. The trial ran a full 3 months before assessing results; nothing shorter has been tested.

You may also see PCOS referred to as polyendocrine metabolic ovarian syndrome (PMOS), the name a 2026 global consensus of more than 50 organisations gave the same condition. None of the evidence above changes under either name; this article uses PCOS because that is still what most readers search.